ES2059577T3 - Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion. - Google Patents

Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.

Info

Publication number
ES2059577T3
ES2059577T3 ES89101583T ES89101583T ES2059577T3 ES 2059577 T3 ES2059577 T3 ES 2059577T3 ES 89101583 T ES89101583 T ES 89101583T ES 89101583 T ES89101583 T ES 89101583T ES 2059577 T3 ES2059577 T3 ES 2059577T3
Authority
ES
Spain
Prior art keywords
hiv
chemical
preparation
antibodies
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89101583T
Other languages
English (en)
Inventor
Hiroaki Maeda
Yasuyuki Eda
Kazuhiko Kimachi
Sachio Tokiyoshi
Shuzo Matsushita
Toshio Hattori
Kiyoshi Takatsuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of ES2059577T3 publication Critical patent/ES2059577T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBEN NUEVOS ANTICUERPOS DEL VIRUS (HIV) PARA LA INMUNODEFICIENCIA ANTIHUMANA QUIMERICA, QUE COMPRENDEN UNA REGION CONSTANTE DERIVADA DE UN ANTICUERPO MONOCLONAL DE RATON, FRAGMENTOS DE GEN QUE CODIFICAN PARA LA REGION VARIABLE LAS CADENAS H Y L DE LOS ANTICUERPOS ANTI - HIV QUIMERICOS, QUE SON EFECTIVOS PARA LA EXPRESION DE ANTICUERPOS ANTI - HIV QUIMERICOS CON ACTIVIDAD NEUTRALIZADORA HIV, UN TRANSFORMADOR DONDE SE INCORPORAN DICHOS FRAGMENTOS GENETICOS, ANTICUERPOS ANTI - HIV EXPRESADOS A PARTIR DE ESTO Y UN PROCESO PARA SU PREPARACION. LOS ANTICUERPOS ANTI - HIV QUIMERICOS DE LA PRESENTE INVENCION MUESTRAN ACTIVIDAD NEUTRALIZADORA ANTI - HIV Y RESULTAN UTILES EN EL DIAGNOSTICO, TRATAMIENTO Y PREVENCION DEL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA (SIDA) PROVOCADO POR EL HIV SIN EFECTOS SECUNDARIOS COMO CHOQUE ANAFILACTICO O LA ENFERMEDAD DEL SUERO.
ES89101583T 1988-01-30 1989-01-30 Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion. Expired - Lifetime ES2059577T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2025588 1988-01-30
JP63171385A JP2646007B2 (ja) 1988-01-30 1988-07-08 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法

Publications (1)

Publication Number Publication Date
ES2059577T3 true ES2059577T3 (es) 1994-11-16

Family

ID=26357160

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89101583T Expired - Lifetime ES2059577T3 (es) 1988-01-30 1989-01-30 Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.

Country Status (5)

Country Link
EP (1) EP0327000B1 (es)
JP (1) JP2646007B2 (es)
AU (1) AU613699B2 (es)
DE (1) DE68907735T2 (es)
ES (1) ES2059577T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
WO1991007493A1 (en) * 1989-11-13 1991-05-30 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
CA2044627A1 (en) * 1989-11-13 1991-05-14 Randy R. Robinson Chimeric mouse human antibodies with specificity to hiv antigens
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2153165C (en) * 1993-01-14 2003-05-06 Hiroaki Maeda Recombinant anti-hiv antibody and process for preparing the same
WO1995007301A1 (en) * 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.

Also Published As

Publication number Publication date
DE68907735D1 (de) 1993-09-02
EP0327000A2 (en) 1989-08-09
DE68907735T2 (de) 1994-01-05
AU613699B2 (en) 1991-08-08
EP0327000B1 (en) 1993-07-28
AU2895489A (en) 1989-08-10
JP2646007B2 (ja) 1997-08-25
JPH022352A (ja) 1990-01-08
EP0327000A3 (en) 1990-05-30

Similar Documents

Publication Publication Date Title
ES2059577T3 (es) Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.
ES2053413T3 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
ES2139017T3 (es) Compuestos que inhiben la replicacion del vih.
NO951212D0 (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
Silvestris et al. Autoreactivity in HIV-1 infection: the role of molecular mimicry
DK0690132T3 (da) Monoklonalt anti-HIV-antistof
Dugast et al. Independent evolution of Fc‐and Fab‐mediated HIV‐1‐specific antiviral antibody activity following acute infection
Holl et al. Involvement of FcγR I (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages
ES2096590T3 (es) Reactivos biespecificos para la terapia del sida.
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
ATE151638T1 (de) Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
Gach et al. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study
DE69332911D1 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
ATE276276T1 (de) Rekombinanter anti-hiv antikörper und seine herstellung
KR930702509A (ko) 사람 면역결핍 바이러스(hiv)면역치료제
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
Symmonds et al. Making a monkey out of human immunodeficiency virus/simian immunodeficiency virus pathogenesis: immune cell depletion experiments as a tool to understand the immune correlates of protection and pathogenicity in HIV infection
Kutzler et al. The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine
ATE128733T1 (de) Monoklonale antikörper gegen hiv gp120.
AR004388A1 (es) Anticuerpos que reconocen cadenas de azucares y remedios para enfermedades infecciosas por vih
MARTINEZ et al. Molecular basis of B cell development and function

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 327000

Country of ref document: ES